Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Exiqon, Alnylam, Life Technologies, and More


Title: Methods for Quantification of microRNAs and Small Interfering RNAs

Patent Number: 8,383,344

Filed: June 1, 2009

Lead Inventor: Nana Jacobsen, Exiqon

“The invention relates to ribonucleic acids, probes, and methods for detection, quantification, as well as monitoring the expression of mature microRNAs and small interfering RNAs,” the patent's abstract states. “The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts. The invention furthermore relates to methods for detection, quantification, as well as monitoring the expression of deoxy-nucleic acids.”

Title: Methods and Compositions for RNA Interference

Patent Number: 8,383,599

Filed: May 16, 2008

Lead Inventor: Gregory Hannon, Cold Spring Harbor Laboratory

The invention, the patent's abstract states, “provides methods for attenuating gene expression in a cell using gene-targeted double-stranded RNA. The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited.”

Title: RNAi Modulation of SCAP and Therapeutic Uses Thereof

Patent Number: 8,383,805

Filed: April 5, 2011

Lead Inventor: Juergen Soutschek, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a SCAP gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19 [to] 25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene,” according to the patent's abstract. “The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.”

Title: microRNA and Methods for Inhibiting Same

Patent Number: 8,383,807

Filed: Nov. 29, 2011

Lead Inventor: Markus Stoffel, Rockefeller University

“The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA,” the patent's abstract states. “In another embodiment, the invention relates to isolated single-stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.”

Title: Nanogenomics for Medicine: siRNA Engineering

Application Number: 20130045243

Filed: July 10, 2012

Lead Inventor: Ancha Baranova, George Mason University

The invention, the patent application's abstract states, comprises “materials and methods for the delivery of siRNA and the production of nanoparticles useful for the delivery of siRNA. Methods of treating a disease or disorder using the nanoparticles described herein also are disclosed.”

Title: Double-Stranded Oligonucleotides

Application Number: 20130045520

Filed: Oct. 20, 2011

Inventor: Tod Woolf, Life Technologies

The patent application, its abstract states, claims “antisense sequences, including duplex RNAi compositions, [that] possess improved properties over those taught in the prior art. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.”